Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Soft Tissue Sarcoma and Renal Cell Carcinoma

NCT02795819 is registered in ClinicalTrials.gov with Virginia Commonwealth University as lead sponsor.

NCT NCT02795819
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02795819 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Soft Tissue Sarcoma and Renal Cell Carcinoma
Lead sponsor
Virginia Commonwealth University
Phase
Phase 1
Overall status
Terminated
Start date
July 8, 2016
Completion date
March 14, 2019
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic disease, renal cell carcinoma, soft tissue sarcoma